News Snapshot:
Genetic Analysis AS and Thalys Medical Technology Group enter Microbiome Laboratory Developed Test (LDT) agreement for the Chinese market OSLO, NORWAY/SHANGHAI, CHINA – 13. January 2022: Microbiome DX company Genetic Analysis AS (“GA”) and Thalys Medical Technology Group Corporation (“Thalys”) announces today that the parties have entered a Laboratory Developed Test (LDT) agreement to evaluate and develop innovative diagnostic solutions for the rapidly growing human microbiota market in China. Thalys will use its Shanghai-based Medical Lab group to further develop and distribute tests based on Genetic Analysis’s GA-map® technology. Over the recent years, the Chinese human microbiome market has been...
